✓ Translated by DotMD AI Clinical Council Source: European journal of cancer (Oxford, England : 1990) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40010135 ↗

Phase III Randomized Trial: Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial (N = 178)

Original Paper Title: “Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 178
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.
  • Study Design & Sample: Phase III Randomized Trial published in European journal of cancer (Oxford, England : 1990) (N = 178 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in European journal of cancer (Oxford, England : 1990) (2025), this phase iii randomized trial evaluating 178 human participants investigated: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC), but recurrence rates remain high. Key clinical takeaway: These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (European journal of cancer (Oxford, England : 1990), 2025-03-26; N = 178; Rigor 82/100): These findings suggest the need to reconsider maintenance therapy strategies after CCRT for potentially shifting away from cytotoxic chemotherapy towards alternative methods to enhance survival outcomes in patients with LACC.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: cervical-cancer → Condition: glucagonoma → Condition: giant-cell-tumor-of-soft-parts →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40010135: Phase III Randomized Trial: Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial (N = 178)

3 of 3 Free Questions Remaining